The new AML mouse model is generated by injecting mice with AML luciferase tumour cell lines, enabling disease progression monitoring by bioluminescence imaging. Using this model, researchers will be able to more efficiently see how their AML therapies behave in vivo, while gaining an understanding of the functional characterization of AML pathogenesis.
“AML is the most common type of leukaemia in adults, yet the challenging nature of the disease means the 5-year survival rate is still under 30 percent,” said Dr Sébastien Tabruyn, General Manager and Chief Scientific Officer (CSO), TransCure bioServices. “Our new mouse model represents a significant advance for those trying to develop new AML therapies by providing a greater understanding of what AML looks like, and how treatments affect it.
In combination with our other research tools, including flow cytometry and immune profiling, we can support researchers to run more human-relevant preclinical studies and develop truly efficacious therapies for this aggressive cancer.”
For more information on TransCure bioServices’ new CDX models for AML, visit: https://transcurebioservices.com/news/what-can-we-do-for-you-new-cdx-models-for-aml-studies
Digital issue: Please click here for more information